Midterm Plan to Overcome Generic Versions of Actos, Setting Sights on Emerging Markets: Takeda

Yasuchika Hasegawa, President, Takeda Pharmaceutical Takeda Pharmaceutical announced on May 11 a three-year midterm plan starting from FY2012 and a company outlook through FY2016. In order to overcome the impact of generic versions of the type 2 diabetes treatment Actos...read more